Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD

Blood (2015) 126 (23): 331.

https://doi.org/10.1182/blood.V126.23.331.331

Published: 2015

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Catherine Cargo, MB FRCPath, Nicola Rowbotham, PhD, Paul Evans, PhD, Sharon Barrans, PhD, Simon Crouch, PhD, Andrew Jack, PhD

Blood (2014) 124 (21): 167.

https://doi.org/10.1182/blood.V124.21.167.167

Published: 2014

Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci

Blood (2014) 124 (21): 1723.

https://doi.org/10.1182/blood.V124.21.1723.1723

Published: 2014

Journal Articles

Detection of BCL2 Gene Rearrangements in the Reed-Sternberg Cells of Composite Lymphomas or Newly Diagnosed Hodgkin Lymphoma in Patients with a Previous Diagnosis of Follicular Lymphoma

Sheila J M O'Connor, PhD, Kathryn Turner, MSc, Catherine H Burton, MBBChir, MD MRCP, FRCPath, Andrew Jack, PhD

Blood (2014) 124 (21): 137.

https://doi.org/10.1182/blood.V124.21.137.137

Published: 2014

Journal Articles

Bone Marrow Staging For Lymphoma: A Re-Evaluation Of Clinical Utility

Andrew Jack, PhD, Daniel Painter, BSc, Alexandra Smith, PhD, Eve Roman, PhD, Ruth M de Tute, MSc, Russell Patmore, MD

Blood (2013) 122 (21): 4278.

https://doi.org/10.1182/blood.V122.21.4278.4278

Published: 2013

Journal Articles

Skeletal-Related Events In Myeloma: A Population-Based Study

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Bagguley Timothy, MSc, Alexandra Smith, PhD, Han-I Wang, PhD, Debra Howell, PhD, Hazem A Sayala, MBChB, MRCP, Gordon Cook, MD, PhD, Andrew Jack, PhD, Russell Patmore, MD, Eve Roman, PhD

Blood (2013) 122 (21): 3158.

https://doi.org/10.1182/blood.V122.21.3158.3158

Published: 2013

Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 3013.

https://doi.org/10.1182/blood.V122.21.3013.3013

Published: 2013

Journal Articles

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Alexandra Smith, PhD, Eve Roman, PhD, Daniel Painter, BSc, Debra Howell, PhD, Graeme Smith, MD, Paul Evans, Russell Patmore, MD, Andrew Jack, PhD

Blood (2013) 122 (21): 4036.

https://doi.org/10.1182/blood.V122.21.4036.4036

Published: 2013

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Mary Gleeson, FRCPath, Wendi Qian, PhD, David Cunningham, FMedSci, Eliza Hawkes, FRACP, Andrew Jack, PhD, Paul Smith, MSc, Paul Mouncey, MSc, Christopher Pocock, PhD, Kirit M Ardeshna, FRCPath, John Radford, MD, Andrew McMillan, FRCPath, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter Johnson, FRCP, Joanna Gambell, BSc, David Linch, FMedSci

Blood (2013) 122 (21): 4268.

https://doi.org/10.1182/blood.V122.21.4268.4268

Published: 2013

Journal Articles

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Sharon Barrans, PhD, Sha Chulin, Alex Smith, Simon Crouch, MA PhD, Lisa Worrillow, PhD, Eve Roman, PhD, David Westhead, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 74.

https://doi.org/10.1182/blood.V122.21.74.74

Published: 2013

Journal Articles

The Prognosis Of Transformed Follicular Lymphoma Is Determined By Prior Exposure To Chemotherapy

Andrew Jack, PhD, Alexandra Smith, PhD, Ruth de Tute, Daniel Painter, BSc, Eve Roman, PhD, Russell Patmore, MD

Blood (2013) 122 (21): 78.

https://doi.org/10.1182/blood.V122.21.78.78

Published: 2013

Journal Articles

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Kirit M Ardeshna, MD, Peter Hoskin, Paul Smith, PhD, Nicholas Chadwick, Nivette Braganca, Wai-Lup Wong, MD, Irfan Kayani, Bal Sanghera, Patricia Diez, Helen Lucraft, Andrew Jack, PhD, MB, Christopher J McNamara, George Mikhaeel, MD, Scott Marshall, MD, Ruth Pettengell, Robert E. Marcus, MBBS, FRCP, FRCPath, Anton Kruger, David C Linch, MD FMedSci

Blood (2012) 120 (21): 1621.

https://doi.org/10.1182/blood.V120.21.1621.1621

Published: 2012

Journal Articles

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Ruth M de Tute, Eve Roman, Andrew Jack, PhD, MB, Roger G Owen, MD, Andy Rawstron, PhD

Blood (2011) 118 (21): 2652.

https://doi.org/10.1182/blood.V118.21.2652.2652

Published: 2011

Journal Articles

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

Matthew Care, PhD, Sharon Barrans, PhD, Lisa Worrillow, Andrew Jack, PhD, MB, David Westhead, PhD, Reuben Tooze, PhD

Blood (2011) 118 (21): 3682.

https://doi.org/10.1182/blood.V118.21.3682.3682

Published: 2011

Journal Articles

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

Simon Rule, MD, Paul Smith, Peter W Johnson, MD, Simon Bolam, MD, George A Follows, Jo Gambell, Peter Hillmen, MBChB, PhD, Andrew Jack, PhD, MB, Stephen A. N. Johnson, MBBS, FRCP, FRCPath, Amy Kirkwood, Anton Kruger, MBChB, FRCP, FRCPath, John F. Seymour, MD, PhD, Milena Toncheva, Jan Walewski, MD, PhD, David C Linch, MD FMedSci

Blood (2011) 118 (21): 440.

https://doi.org/10.1182/blood.V118.21.440.440

Published: 2011

Journal Articles

A Unified Prognostic Model for Myelodysplastic Syndrome and Acute Myeloid Leukaemia Based on Flow Cytometric Blast Count

Alexandra Smith, BSc PhD, Simon Crouch, MA PhD, Dan Painter, Eve Roman, Matt Cullen, Fiona Bennett, Catherine Cargo, MB, MRCP, Andrew Jack, PhD, MB

Blood (2011) 118 (21): 1736.

https://doi.org/10.1182/blood.V118.21.1736.1736

Published: 2011

NARROW

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Detection of BCL2 Gene Rearrangements in the Reed-Sternberg Cells of Composite Lymphomas or Newly Diagnosed Hodgkin Lymphoma in Patients with a Previous Diagnosis of Follicular Lymphoma

Bone Marrow Staging For Lymphoma: A Re-Evaluation Of Clinical Utility

Skeletal-Related Events In Myeloma: A Population-Based Study

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Prognostic Effect Of More Than 1 Extranodal Site Of Disease For Patients With Diffuse Large B Cell Lymphoma (DLBCL) In The Rituximab Era: Results From The UK NCRI R-CHOP 14 Versus 21 Trial

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

The Prognosis Of Transformed Follicular Lymphoma Is Determined By Prior Exposure To Chemotherapy

Young Adults Aged 18 to 30 Years with Hodgkin Lymphoma Can Tolerate a Modified Version of the Combined Modality German Paediatric HD95 Protocol with Minimal Neurotoxicity and Excellent Outcome. Results of the UK NCRN 18–30 Study (CRUK/08/012)

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial

A Unified Prognostic Model for Myelodysplastic Syndrome and Acute Myeloid Leukaemia Based on Flow Cytometric Blast Count

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only